


In the Claims:

Claims 1-14. (canceled)

15. (currently amended) A polypharmacophore represented by formula (II):



wherein:

R₁ is -CO₂R₄ or -CON(R₄)₂;

R₂ represents independently for each occurrence H, F, Cl, Br, or I;

R₃ represents independently for each occurrence H, F, Cl, Br, or I;

R₄ represents independently for each occurrence H or alkyl; and

the stereochemical configuration of the carbon-carbon double bond is Z, E, or a

mixture of Z and E.

Claims 16-54. (canceled)


55. (previously presented) The polypharmacophore of claim 15, wherein R₂ is F.

56. (previously presented) The polypharmacophore of claim 15, wherein R₂ is F and R₃ is H.

57. (canceled)

58. (currently amended) The polypharmacophore of claim 15, wherein R_4 is CO_2R_4 and R_4 is H.


59. (currently amended) The polypharmacophore of claim 15, wherein said compound is selected from the group consisting of:




60. (currently amended) A pharmaceutical composition, comprising:

a polypharmacophore of claim 15, 55, 56, [[57,]] 58 or 59, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier.

61. (currently amended) A polypharmacophore selected from the group consisting of:





62. (previously presented) A pharmaceutical composition, comprising: a polypharmacophore of claim 61, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier.